Anti-chitinase-3-like protein 1 antibody

Abstract

The anti-chitinase-3-like protein 1 antibody or the antigen binding fragment thereof comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises a CDR of a table 1, and the heavy chain variable region comprises a CDR of a table 2.

Description

Technical Field

[0001] The present invention relates to an antibody against chitinase-3-like protein 1. More specifically, the present invention relates to an antibody that can specifically bind to chitinase-3-like protein 1 (CHI3L1) and can be used to prevent or treat CHI3L1-related diseases or to diagnose the disease. Background Art

[0002] It is well known that chitinase-3-like protein 1 (CHI3L1) is used to induce the promotion of cancer metastasis, the suppression of immune function and the inhibition of cell apoptosis, and is closely related to the occurrence and progression of cancer diseases such as inflammatory response and angiogenesis.

[0003] CHI3L1 is normally expressed at a low level, but its expression is reported to be significantly increased in the blood and tissues of cancer patients or patients with inflammatory diseases, highlighting its potential as a diagnostic indicator for various diseases.

[0004] Therefore, the present inventors attempted to develop antibodies or antibody-related molecules that can be used for preventing, treating or diagnosing CHI3L1-related diseases by specifically binding to CHI3L1 as described above.

[0005] As a related prior art document, there is US Patent No. 7,670,599. Summary of the invention

[0006] Problem that the invention aims to solve

[0007] The main object of the present invention is to provide a novel antibody that can specifically bind to chitinase-3-like protein 1 (CHI3L1).

[0008] Another object of the present invention is to use the antibody to provide a pharmaceutical composition for preventing or treating a CHI3L1-related disease, a composition for diagnosing the disease, a kit for diagnosing the disease, and a method for providing information for diagnosing the disease.

[0009] Another object of the present invention is to provide polynucleotides, vectors and cells that can be used to produce the antibodies.

[0010] Means used to solve problems

[0011] According to one aspect of the present invention, the present invention provides an antibody or an antigen-binding fragment thereof, which is an anti-chitinase-3-like protein 1 (anti-CHI3L1) antibody or an antigen-binding fragment thereof, comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises CDR1 of SEQ ID NO:1, CDR2 of SEQ ID NO:2, and CDR3 of SEQ ID NO:3, and the heavy chain variable region comprises CDR1 of SEQ ID NO:31, CDR2 of SEQ ID NO:32, and CDR3 of SEQID NO:33; comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises CDR1 of SEQ ID NO:4, CDR2 of SEQ ID NO:5, and CDR3 of SEQID NO:6, and the heavy chain variable region comprises CDR1 of SEQ ID NO:34, CDR2 of SEQID NO:35, and CDR3 of SEQID NO:36; comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises CDR1 of SEQ ID NO:7, CDR2 of SEQ ID NO:8, and CDR3 of SEQID NO:9. NO:8, CDR2 of SEQ ID NO:9, and CDR3 of SEQ ID NO:9, the heavy chain variable region comprising CDR1 of SEQ ID NO:37, CDR2 of SEQ ID NO:38, and CDR3 of SEQ ID NO:39; comprising a light chain variable region and a heavy chain variable region, the light chain variable region comprising CDR1 of SEQ ID NO:10, CDR2 of SEQ ID NO:11, and CDR3 of SEQ ID NO:12, the heavy chain variable region comprising CDR1 of SEQ ID NO:40, CDR2 of SEQ ID NO:41, and CDR3 of SEQ ID NO:42; comprising a light chain variable region and a heavy chain variable region, the light chain variable region comprising CDR1 of SEQ ID NO:13, CDR2 of SEQ ID NO:14, and CDR3 of SEQ ID NO:15, the heavy chain variable region comprising CDR1 of SEQ ID NO:43, CDR2 of SEQ ID NO:44, and CDR3 of SEQ ID NO:45. NO:45; comprising a light chain variable region and a heavy chain variable region, the light chain variable region comprising CDR1 of SEQ ID NO:16, CDR2 of SEQ ID NO:17, and CDR3 of SEQ ID NO:18, and the heavy chain variable region comprising CDR1 of SEQ ID NO:46, CDR2 of SEQ ID NO:47, and CDR3 of SEQ ID NO:48;The invention comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises CDR1 of SEQ ID NO: 19, CDR2 of SEQ ID NO: 20, and CDR3 of SEQ ID NO: 21, and the heavy chain variable region comprises CDR1 of SEQ ID NO: 49, CDR2 of SEQ ID NO: 50, and CDR3 of SEQ ID NO: 51; the invention comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises CDR1 of SEQ ID NO: 22, CDR2 of SEQ ID NO: 23, and CDR3 of SEQ ID NO: 24, and the heavy chain variable region comprises CDR1 of SEQ ID NO: 52, CDR2 of SEQ ID NO: 53, and CDR3 of SEQ ID NO: 54; the invention comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises CDR1 of SEQ ID NO: 25, CDR2 of SEQ ID NO: 26, and CDR3 of SEQ ID NO: 27, and the heavy chain variable region comprises CDR1 of SEQ ID NO: 28, CDR2 of SEQ ID NO: 29, and CDR3 of SEQ ID NO: 30 NO:55 CDR1, SEQ ID NO:56 CDR2 and SEQ ID NO:57 CDR3; or comprising a light chain variable region and a heavy chain variable region, the light chain variable region comprising CDR1 of SEQ ID NO:28, CDR2 of SEQ ID NO:29 and CDR3 of SEQ ID NO:30, the heavy chain variable region comprising CDR1 of SEQ ID NO:58, CDR2 of SEQ ID NO:59 and CDR3 of SEQ ID NO:60. ;

[0012] According to another aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating a CHI3L1-related disease comprising the antibody or antigen-binding fragment thereof of the present invention.

[0013] According to another aspect of the present invention, the present invention provides a composition for diagnosing a CHI3L1-related disease comprising the antibody or antigen-binding fragment thereof of the present invention.

[0014] According to another aspect of the present invention, the present invention provides a kit for diagnosing a CHI3L1-related disease comprising the diagnostic composition of the present invention.

[0015] According to another aspect of the present invention, the present invention provides an information providing method for diagnosing CHI3L1-related diseases, the method comprising: a step of contacting the antibody or antigen-binding fragment thereof of the present invention with a sample separated from a subject; and a step of determining a complex formed by the antibody or antigen-binding fragment thereof and CHI3L1 through the contact.

[0016] According to another aspect of the present invention, the present invention provides a polynucleotide encoding the antibody or antigen-binding fragment thereof of the present invention.

[0017] According to yet another aspect of the present invention, the present invention provides a vector comprising the polynucleotide of the present invention.

[0018] According to still another aspect of the present invention, the present invention provides a cell transformed by the vector of the present invention.

[0019] Effects of the Invention

[0020] The antibody or antigen-binding fragment thereof of the present invention can specifically bind to chitinase-3-like protein 1 (CHI3L1), and thus can be used for the prevention or treatment of CHI3L1-related diseases, and the diagnosis of the diseases. Thus, when the composition, kit, and information providing method of the present invention are used, CHI3L1-related diseases can be effectively prevented, treated, or diagnosed. In addition, when the polynucleotide, vector, and cell of the present invention are used, the antibody or antigen-binding fragment thereof of the present invention having the excellent effects as described above can be effectively prepared. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 Part A is a schematic diagram showing the process of screening antibodies showing significant binding ability to human CHI3L1 (hCHI3L1) by phage display, Figure 1 Part B to Figure 1 Part D shows the panning titration results for Fab-I (antigen binding fragment-I) and Fab-II, respectively.

[0022] Figure 2 The results of investigating the amino acid length distribution of heavy chain CDR3 (HCDR3) of 10 antibodies (A5, A7, D2, F2, E7, F4, H1, 1E12, C5, and H7) against hCHI3L1 screened by phage display are shown.

[0023] Figure 3 Part A shows the results of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) for confirming the production of IgG from 10 clones (A5, A7, D2, F2, E7, F4, H1, 1E12, C5, and H7) having antibodies against hCHI3L1. Figure 3 Part B shows the results of the determination of IgG production.

[0024] Figure 4 Part A to Figure 4 Part B shows the EC values ​​of 10 antibodies against hCHI3L1 determined by enzyme-linked immunosorbent assay (ELISA).50 The result of the value.

[0025] Figure 5 The graph shows the results of measuring the number of migrated cells after treating A549 cell lines with antibodies A5, A7, D2, F2, E7, F4, H1, 1E12, C5, and H7 against hCHI3L1 as candidate antibodies. DETAILED DESCRIPTION

[0026] The antibody or antigen-binding fragment thereof of the present invention is discovered by phage display panning using chitinase-3-like protein 1 (CHI3L1) as an antigen, and can specifically bind to CHI3L1.

[0027] CHI3L1, also known as YKL-40, is known to be involved in various cancers, cancer metastasis, immune function, and cell apoptosis.

[0028] The present invention provides 10 types of antibodies or antigen-binding fragments thereof.

[0029] As shown in Tables 1 to 4, the 10 types are named "A5", "A7", "D2", "F2", "E7", "F4", "H1", "1E12", "C5", and "H7", respectively. Each type of antibody or antigen-binding fragment thereof is characterized in that the amino acid sequences of CDR1, CDR2, and CDR3 (from the meaning of CDR in the light chain variable region, they are respectively expressed as "CDRL1", "CDRL2", and "CDRL3" in Table 1) in the light chain variable region are shown in Table 1, and the amino acid sequences of CDR1, CDR2, and CDR3 (from the meaning of CDR in the heavy chain variable region, they are respectively expressed as "CDRH1", "CDRH2", and "CDRH3" in Table 2) in the heavy chain variable region are shown in Table 2.

[0030] In one embodiment, the amino acid sequence of the light chain variable region of each type of antibody or antigen-binding fragment thereof is shown in Table 3, and the amino acid sequence of the heavy chain variable region thereof is shown in Table 4.

[0031] The antibody or antigen-binding fragment thereof of the present invention may be in various forms satisfying the above conditions, for example, it may be an antibody selected from the group consisting of IgG, IgA, IgM, IgE and IgD, or it may be a fragment selected from the group consisting of Fab (fragment antigen binding), Fab', F(ab')2, scFv, scFv-Fc, diabody, minibody and triabody.

[0032] The antibody or antigen-binding fragment thereof of the present invention may be labeled for detection. In this case, for example, the label may be formed by direct or indirect binding of a detectable labeling substance.

[0033] Experiments have shown that the antibody or antigen-binding fragment thereof of the present invention can specifically bind to CHI3L1 with high binding capacity. Therefore, the antibody or antigen-binding fragment thereof of the present invention can be used to prevent or treat CHI3L1-related diseases, and can also be used to diagnose CHI3L1-related diseases.

[0034] Therefore, the present invention provides a pharmaceutical composition for preventing or treating a CHI3L1-related disease comprising the antibody or antigen-binding fragment thereof of the present invention.

[0035] In addition, the present invention provides a composition for diagnosing a CHI3L1-related disease comprising the antibody or antigen-binding fragment thereof of the present invention.

[0036] In addition, the present invention provides a kit for diagnosing a CHI3L1-related disease comprising the antibody or antigen-binding fragment thereof of the present invention or the diagnostic composition of the present invention.

[0037] In addition, the present invention provides an information providing method for diagnosing CHI3L1-related diseases, the method comprising: a step of contacting the antibody or its antigen-binding fragment of the present invention with a sample separated from a subject; and a step of measuring the complex formed by the antibody or its antigen-binding fragment and chitinase-3-like protein 1 through the contact.

[0038] In one embodiment of the present invention, the CHI3L1-related disease is cancer, cancer metastasis, arthritis or dementia, but is not limited thereto. In one embodiment, the CHI3L1-related disease is lung cancer metastasis.

[0039] The pharmaceutical composition for preventing or treating CHI3L1-related diseases of the present invention is characterized in that it contains the antibody or antigen-binding fragment thereof of the present invention as described above. The pharmaceutical composition of the present invention may contain more than one type of the antibody or antigen-binding fragment thereof of the present invention, or may contain all 10 types. The pharmaceutical composition of the present invention may be the antibody or antigen-binding fragment thereof of the present invention itself, or may be in the form of a mixture with a pharmaceutically acceptable carrier. The pharmaceutical composition of the present invention can be administered orally or parenterally during clinical administration, and can be used in the form of a general pharmaceutical preparation. The pharmaceutical composition of the present invention can be used alone or in combination with methods using surgery, radiotherapy, hormone therapy, chemotherapy, and biological response modifiers. The pharmaceutical composition of the present invention can be administered at the same dose as a conventional antibody preparation based on the antibody or antigen-binding fragment thereof of the present invention contained therein. For example, based on the antibody or antigen-binding fragment thereof of the present invention, it can be administered at about 1 kg / kg body weight to 10 kg / kg body weight, but its range will vary depending on the weight, age, sex, health status, diet, administration time, administration method, excretion rate, and severity of the disease of the subject of administration. When administered clinically, it can be formulated into various oral or parenteral dosage forms, in which case commonly used diluents or excipients, such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, etc., can be used.

[0040] The composition for diagnosing CHI3L1-related diseases of the present invention is characterized in that it comprises the antibody or antigen-binding fragment thereof of the present invention as described above. As in the case of the pharmaceutical composition, the diagnostic composition of the present invention may also comprise one or more types of the antibody or antigen-binding fragment thereof of the present invention, or may comprise all 10 types. The diagnostic composition of the present invention may comprise other antibodies or antigen-binding fragments thereof in addition to the antibody or antigen-binding fragment thereof of the present invention. In addition, it may also comprise a substance required for the binding reaction between the antibody or antigen-binding fragment thereof of the present invention and the antigen, such as a reagent. In addition, it may also comprise a substance required for detecting the binding, a substance for stabilizing the antibody or antigen-binding fragment thereof of the present invention, and the like.

[0041] The kit for diagnosing a CHI3L1-related disease of the present invention is characterized in that it comprises the diagnostic composition of the present invention. In addition to the diagnostic composition of the present invention, the diagnostic kit of the present invention may also include reagents and instruments required for diagnosing a CHI3L1-related disease using the diagnostic composition of the present invention, such as reagents and instruments required for detecting the binding between the antibody or antigen-binding fragment thereof of the present invention and an antigen.

[0042] The information providing method for diagnosing CHI3L1-related diseases of the present invention is characterized in that the method comprises: a step of contacting the antibody or its antigen-binding fragment of the present invention with a sample separated from a subject; and a step of determining the complex formed by the antibody or its antigen-binding fragment and CHI3L1 through the contact. In the information providing method of the present invention, the subject can be a mammal, preferably a human. In the information providing method of the present invention, the sample can be a biological sample, such as a sample of tissue, cell, body fluid, etc. separated from the subject, and can be blood or serum. In the information providing method of the present invention, the determination of the complex can be achieved using a conventional method for determining the binding complex between an antibody or an antibody-related molecule and an antigen.

[0043] The present invention also provides a polynucleotide encoding the antibody or antigen-binding fragment thereof of the present invention.

[0044] In one embodiment, in the polynucleotide of the present invention, the base sequences of the CDR1, CDR2, and CDR3 (in terms of the meaning of CDR in the light chain variable region, represented as "CDRL1", "CDRL2", and "CDRL3" in Table 5) coding regions of the light chain variable region are as shown in Table 5, and the base sequences of the CDR1, CDR2, and CDR3 (in terms of the meaning of CDR in the heavy chain variable region, represented as "CDRH1", "CDRH2", and "CDRH3" in Table 6) coding regions of the heavy chain variable region are as shown in Table 6.

[0045] In one embodiment, the light chain variable region encoding base sequence of the polynucleotide encoding each type of antibody or antigen-binding fragment thereof of the present invention is shown in Table 7, and the heavy chain variable region encoding base sequence is shown in Table 8.

[0046] The present invention also provides a vector comprising the polynucleotide of the present invention. In one embodiment, the vector of the present invention is composed in a manner that the antibody or antigen-binding fragment thereof encoded by the polynucleotide is expressed in a host cell. In one embodiment, the vector of the present invention includes a replication origin, a promoter, a selection marker, etc. suitable for replication and expression in a host cell.

[0047] The present invention also provides a cell transformed by the vector of the present invention. In one embodiment, the cell of the present invention is a cell capable of expressing an antibody or antigen-binding fragment thereof encoded by a polynucleotide contained in the vector of the present invention, and is a cell in which the vector of the present invention can be replicated.

[0048] The antibodies or antigen-binding fragments thereof of the present invention can be prepared using the amino acid sequence and base sequence information related to the antibodies or antigen-binding fragments thereof of the present invention as described above, the polynucleotides, vectors or cells of the present invention.

[0049] Table 1

[0050]

[0051] Table 2

[0052]

[0053] Table 3

[0054]

[0055] Table 4

[0056]

[0057] Table 5

[0058]

[0059] Table 6

[0060]

[0061] Table 7

[0062]

[0063] Table 8

[0064]

[0065] The present invention is further described in detail below by way of examples. These examples are only used to illustrate the present invention, and therefore, the scope of the present invention should not be construed as being limited by these examples.

[0066] Example

[0067] Example 1. Screening of Fab antibody clones against CHI3L1

[0068] In order to find antibodies that specifically bind to CHI3L1, phage display panning based on immunotubes and magnetic beads was performed using CHI3L1 as an antigen. In order to screen clones that specifically bind to CHI3L1, a monoclonal phage enzyme-linked immunosorbent assay (ELISA) was performed ( Figure 1 ).

[0069] A total of 10 Fab clones were screened by base sequence analysis and amino acid sequence analysis from clones that showed positive results in monoclonal phage ELISA. The results of the examination of the length distribution of the heavy chain CDR3 (HCDR3) of the screened Fab clones showed that clones with 8 residues were confirmed to be 70%, and clones with 6, 7 or 11 residues were confirmed to be 10% ( Figure 2 ).

[0070] Example 2. Expression and purification of IgG antibodies

[0071] The clones screened in Example 1 were converted into IgG forms of human antibodies and subjected to validation experiments. The 10 anti-CHI3L1 antibodies were co-transfected into ExpiCHO-S cells for culture, and IgG was purified using a Protein Aresin column. The molecular weight and purity of the purified IgG antibodies were confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Figure 3 ).

[0072] Example 3. Enzyme-linked immunosorbent assay (ELISA) analysis of antibodies

[0073] Experiments were performed to examine the EC of each antibody by ELISA. 50 The results showed that all 10 antibodies bound to the CHI3L1 antigen protein. 50 In terms of the values, antibodies C5, F4, and 1E12 showed excellent binding abilities ( Figure 4 ).

[0074] Example 4. Analysis of Anticancer Efficacy of Antibodies

[0075] An experiment was conducted to confirm whether the treatment of lung cancer cell lines with antibodies against CHI3L1 has the effect of inhibiting cancer metastasis. The migration of A549 cell line, a human lung cancer cell line, was quantified in permeable inserts. As a result, when 10 antibodies against human CHI3L1 (hCHI3L1) were treated, the number of cells migrating in the A549 cell line decreased compared to the control group ( Figure 5 ).

Claims

1. An antibody or an antigen-binding fragment thereof, which is an anti-chitinase-3-like protein 1 antibody or an antigen-binding fragment thereof, wherein: comprising a light chain variable region and a heavy chain variable region, the light chain variable region comprising CDR1 of SEQ ID NO: 1, CDR2 of SEQ ID NO: 2, and CDR3 of SEQ ID NO: 3, and the heavy chain variable region comprising CDR1 of SEQ ID NO: 31, CDR2 of SEQ ID NO: 32, and CDR3 of SEQ ID NO: 33; comprising a light chain variable region and a heavy chain variable region, the light chain variable region comprising CDR1 of SEQ ID NO:4, CDR2 of SEQ ID NO:5, and CDR3 of SEQ ID NO:6, and the heavy chain variable region comprising CDR1 of SEQ ID NO:34, CDR2 of SEQ ID NO:35, and CDR3 of SEQ ID NO:36; comprising a light chain variable region and a heavy chain variable region, the light chain variable region comprising CDR1 of SEQ ID NO:7, CDR2 of SEQ ID NO:8, and CDR3 of SEQ ID NO:9, and the heavy chain variable region comprising CDR1 of SEQ ID NO:37, CDR2 of SEQ ID NO:38, and CDR3 of SEQ ID NO:39; comprising a light chain variable region and a heavy chain variable region, the light chain variable region comprising CDR1 of SEQ ID NO: 10, CDR2 of SEQ ID NO: 11, and CDR3 of SEQ ID NO: 12, and the heavy chain variable region comprising CDR1 of SEQ ID NO: 40, CDR2 of SEQ ID NO: 41, and CDR3 of SEQ ID NO: 42; comprising a light chain variable region and a heavy chain variable region, the light chain variable region comprising CDR1 of SEQ ID NO: 13, CDR2 of SEQ ID NO: 14, and CDR3 of SEQ ID NO: 15, and the heavy chain variable region comprising CDR1 of SEQ ID NO: 43, CDR2 of SEQ ID NO: 44, and CDR3 of SEQ ID NO: 45; comprising a light chain variable region and a heavy chain variable region, the light chain variable region comprising CDR1 of SEQ ID NO: 16, CDR2 of SEQ ID NO: 17, and CDR3 of SEQ ID NO: 18, and the heavy chain variable region comprising CDR1 of SEQ ID NO: 46, CDR2 of SEQ ID NO: 47, and CDR3 of SEQ ID NO: 48; comprising a light chain variable region and a heavy chain variable region, the light chain variable region comprising CDR1 of SEQ ID NO: 19, CDR2 of SEQ ID NO: 20, and CDR3 of SEQ ID NO: 21, and the heavy chain variable region comprising CDR1 of SEQ ID NO: 49, CDR2 of SEQ ID NO: 50, and CDR3 of SEQ ID NO: 51; comprising a light chain variable region and a heavy chain variable region, the light chain variable region comprising CDR1 of SEQ ID NO:22, CDR2 of SEQ ID NO:23, and CDR3 of SEQ ID NO:24, and the heavy chain variable region comprising CDR1 of SEQ ID NO:52, CDR2 of SEQ ID NO:53, and CDR3 of SEQ ID NO:54; comprising a light chain variable region and a heavy chain variable region, the light chain variable region comprising CDR1 of SEQ ID NO:25, CDR2 of SEQ ID NO:26, and CDR3 of SEQ ID NO:27, and the heavy chain variable region comprising CDR1 of SEQ ID NO:55, CDR2 of SEQ ID NO:56, and CDR3 of SEQ ID NO:57; or It comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises CDR1 of SEQ ID NO:28, CDR2 of SEQ ID NO:29 and CDR3 of SEQ ID NO:30, and the heavy chain variable region comprises CDR1 of SEQ ID NO:58, CDR2 of SEQ ID NO:59 and CDR3 of SEQ ID NO:

60.

2. The antibody or antigen-binding fragment thereof according to claim 1, wherein A light chain variable region comprising SEQ ID NO:61 and a heavy chain variable region comprising SEQ ID NO:71; comprising a light chain variable region of SEQ ID NO:62 and a heavy chain variable region of SEQ ID NO:72; comprising a light chain variable region of SEQ ID NO:63 and a heavy chain variable region of SEQ ID NO:73; comprising a light chain variable region of SEQ ID NO:64 and a heavy chain variable region of SEQ ID NO:74; A light chain variable region comprising SEQ ID NO:65 and a heavy chain variable region comprising SEQ ID NO:75; comprising a light chain variable region of SEQ ID NO:66 and a heavy chain variable region of SEQ ID NO:76; A light chain variable region comprising SEQ ID NO:67 and a heavy chain variable region comprising SEQ ID NO:77; A light chain variable region comprising SEQ ID NO:68 and a heavy chain variable region comprising SEQ ID NO:78; comprising a light chain variable region of SEQ ID NO: 69 and a heavy chain variable region of SEQ ID NO: 79; or It comprises a light chain variable region of SEQ ID NO:70 and a heavy chain variable region of SEQ ID NO:

80.

3. A pharmaceutical composition for preventing or treating chitinase-3-like protein 1-related diseases, wherein: The pharmaceutical composition comprises the antibody or antigen-binding fragment thereof according to claim 1 or 2.

4. The pharmaceutical composition according to claim 3, wherein The chitinase-3-like protein 1-related disease is cancer, cancer metastasis, arthritis or dementia.

5. The pharmaceutical composition according to claim 4, wherein The chitinase-3-like protein 1-related disease is lung cancer metastasis.

6. A composition for diagnosing chitinase-3-like protein 1 related diseases, wherein: The composition comprises the antibody or antigen-binding fragment thereof according to claim 1 or 2.

7. The composition according to claim 6, wherein The chitinase-3-like protein 1-related disease is cancer, cancer metastasis, arthritis or dementia.

8. A kit for diagnosing chitinase-3-like protein 1 related diseases, wherein: Comprising the composition of claim 6.

9. The kit according to claim 8, wherein The chitinase-3-like protein 1-related disease is cancer, cancer metastasis, arthritis or dementia.

10. A method for providing information for diagnosing a chitinase-3-like protein 1-related disease, wherein: include: A step of contacting the antibody or antigen-binding fragment thereof according to claim 1 or 2 with a sample separated from a subject; as well as The step of determining the complex formed by the antibody or antigen-binding fragment thereof and chitinase-3-like protein 1 through the contact.

11. The information providing method according to claim 10, wherein: The chitinase-3-like protein 1-related disease is cancer, cancer metastasis, arthritis or dementia.

12. A polynucleotide, wherein: Encodes the antibody or antigen-binding fragment thereof according to claim 1 or 2.

13. The polynucleotide according to claim 12, wherein Comprising a light chain variable region coding sequence and a heavy chain variable region coding sequence, wherein the light chain variable region coding sequence comprises a CDR1 coding sequence of SEQ ID NO: 81, a CDR2 coding sequence of SEQ ID NO: 82, and a CDR3 coding sequence of SEQ ID NO: 83, and the heavy chain variable region coding sequence comprises a CDR1 coding sequence of SEQ ID NO: 111, a CDR2 coding sequence of SEQ ID NO: 112, and a CDR3 coding sequence of SEQ ID NO: 113; comprising a light chain variable region coding sequence and a heavy chain variable region coding sequence, wherein the light chain variable region coding sequence comprises a CDR1 coding sequence of SEQ ID NO: 84, a CDR2 coding sequence of SEQ ID NO: 85, and a CDR3 coding sequence of SEQ ID NO: 86, and the heavy chain variable region coding sequence comprises a CDR1 coding sequence of SEQ ID NO: 114, a CDR2 coding sequence of SEQ ID NO: 115, and a CDR3 coding sequence of SEQ ID NO: 116; Comprising a light chain variable region coding sequence and a heavy chain variable region coding sequence, wherein the light chain variable region coding sequence comprises a CDR1 coding sequence of SEQ ID NO: 87, a CDR2 coding sequence of SEQ ID NO: 88, and a CDR3 coding sequence of SEQ ID NO: 89, and the heavy chain variable region coding sequence comprises a CDR1 coding sequence of SEQ ID NO: 117, a CDR2 coding sequence of SEQ ID NO: 118, and a CDR3 coding sequence of SEQ ID NO: 119; Comprising a light chain variable region coding sequence and a heavy chain variable region coding sequence, wherein the light chain variable region coding sequence comprises a CDR1 coding sequence of SEQ ID NO: 90, a CDR2 coding sequence of SEQ ID NO: 91, and a CDR3 coding sequence of SEQ ID NO: 92, and the heavy chain variable region coding sequence comprises a CDR1 coding sequence of SEQ ID NO: 120, a CDR2 coding sequence of SEQ ID NO: 121, and a CDR3 coding sequence of SEQ ID NO: 122; Comprising a light chain variable region coding sequence and a heavy chain variable region coding sequence, wherein the light chain variable region coding sequence comprises a CDR1 coding sequence of SEQ ID NO: 93, a CDR2 coding sequence of SEQ ID NO: 94, and a CDR3 coding sequence of SEQ ID NO: 95, and the heavy chain variable region coding sequence comprises a CDR1 coding sequence of SEQ ID NO: 123, a CDR2 coding sequence of SEQ ID NO: 124, and a CDR3 coding sequence of SEQ ID NO: 125; Comprising a light chain variable region coding sequence and a heavy chain variable region coding sequence, wherein the light chain variable region coding sequence comprises a CDR1 coding sequence of SEQ ID NO: 96, a CDR2 coding sequence of SEQ ID NO: 97, and a CDR3 coding sequence of SEQ ID NO: 98, and the heavy chain variable region coding sequence comprises a CDR1 coding sequence of SEQ ID NO: 126, a CDR2 coding sequence of SEQ ID NO: 127, and a CDR3 coding sequence of SEQ ID NO: 128; Comprising a light chain variable region coding sequence and a heavy chain variable region coding sequence, wherein the light chain variable region coding sequence comprises a CDR1 coding sequence of SEQ ID NO: 99, a CDR2 coding sequence of SEQ ID NO: 100, and a CDR3 coding sequence of SEQ ID NO: 101, and the heavy chain variable region coding sequence comprises a CDR1 coding sequence of SEQ ID NO: 129, a CDR2 coding sequence of SEQ ID NO: 130, and a CDR3 coding sequence of SEQ ID NO: 131; Comprising a light chain variable region coding sequence and a heavy chain variable region coding sequence, wherein the light chain variable region coding sequence comprises a CDR1 coding sequence of SEQ ID NO: 102, a CDR2 coding sequence of SEQ ID NO: 103, and a CDR3 coding sequence of SEQ ID NO: 104, and the heavy chain variable region coding sequence comprises a CDR1 coding sequence of SEQ ID NO: 132, a CDR2 coding sequence of SEQ ID NO: 133, and a CDR3 coding sequence of SEQ ID NO: 134; comprising a light chain variable region coding sequence and a heavy chain variable region coding sequence, wherein the light chain variable region coding sequence comprises a CDR1 coding sequence of SEQ ID NO: 105, a CDR2 coding sequence of SEQ ID NO: 106, and a CDR3 coding sequence of SEQ ID NO: 107, and the heavy chain variable region coding sequence comprises a CDR1 coding sequence of SEQ ID NO: 135, a CDR2 coding sequence of SEQ ID NO: 136, and a CDR3 coding sequence of SEQ ID NO: 137; or It comprises a light chain variable region coding sequence and a heavy chain variable region coding sequence, wherein the light chain variable region coding sequence comprises the CDR1 coding sequence of SEQ ID NO: 108, the CDR2 coding sequence of SEQ ID NO: 109 and the CDR3 coding sequence of SEQ ID NO: 110, and the heavy chain variable region coding sequence comprises the CDR1 coding sequence of SEQ ID NO: 138, the CDR2 coding sequence of SEQ ID NO: 139 and the CDR3 coding sequence of SEQ ID NO:

140.

14. The polynucleotide according to claim 13, wherein A light chain variable region encoding sequence comprising SEQ ID NO: 141 and a heavy chain variable region encoding sequence comprising SEQ ID NO: 151; A light chain variable region encoding sequence comprising SEQ ID NO: 142 and a heavy chain variable region encoding sequence comprising SEQ ID NO: 152; A light chain variable region encoding sequence comprising SEQ ID NO: 143 and a heavy chain variable region encoding sequence comprising SEQ ID NO: 153; A light chain variable region encoding sequence comprising SEQ ID NO: 144 and a heavy chain variable region encoding sequence comprising SEQ ID NO: 154; A light chain variable region encoding sequence comprising SEQ ID NO: 145 and a heavy chain variable region encoding sequence comprising SEQ ID NO: 155; A light chain variable region encoding sequence comprising SEQ ID NO: 146 and a heavy chain variable region encoding sequence comprising SEQ ID NO: 156; A light chain variable region encoding sequence comprising SEQ ID NO: 147 and a heavy chain variable region encoding sequence comprising SEQ ID NO: 157; A light chain variable region encoding sequence comprising SEQ ID NO: 148 and a heavy chain variable region encoding sequence comprising SEQ ID NO: 158; A light chain variable region encoding sequence comprising SEQ ID NO: 149 and a heavy chain variable region encoding sequence comprising SEQ ID NO: 159; or Contains the light chain variable region encoding sequence of SEQ ID NO: 150 and the heavy chain variable region encoding sequence of SEQ ID NO:

160.

15. A vector, wherein Comprising the polynucleotide of claim 12.

16. A cell, wherein: Transformed by the vector of claim 15.

Images